mydrugindex
Kenyan Reference & Directory
Free lookups today: 2/3 · Unlimited with Pro Subscribe from KES 99
Free lookups: 2/3 Unlimited with Pro → Browse by class Interactions · Tip: type at least 2 letters, then pick a result

INN monograph

Chloramphenicol

Therapeutic agent (verify pharmacological class) · POM

POM

Verified · Updated 01 Aug 2026 · Source: Local active-ingredient clinical extract; FDA drug label via OpenFDA/DailyMed; Professional class pharmacology (Therapeutic agent (verify pharmacological class))

Class
Therapeutic agent (verify pharmacolo...
Schedule
POM
Route
INTRAVENOUS
Onset
Product-specific
Duration
Product-specific
Pregnancy
Pregnancy Pregnancy Cate...
Renal
Review renal impairment...
High-alert
No

Kenya market

Wholesale / list prices where loaded

From
Median
Brands
7
Boxed / critical warning

WARNING Serious and fatal blood dyscrasias (aplastic anemia, hypoplastic anemia, thrombocytopenia and granulocytopenia) are known to occur after the administration of chloramphenicol. In addition, there have been reports of aplastic anemia attributed to chloramphenicol which later terminated in leukemia. Blood dyscrasias have occurred after both short-term and prolonged therapy with this drug. Chloramphenicol must not be used when less potentially dangerous agents will be effective, as described in the INDICATIONS AND USAGE section. It must not be used in the treatment of trivial infections or where it is not indicated, as in colds, influenza, infections of the throat; or as a prophylactic agent to prevent bacterial infections. Precautions: It is essential that adequate blood studies be made during treatment with the drug. While blood studies may detect early peripheral blood changes, such as leukopenia, reticulocytopenia, or granulocytopenia, before they become irreversible, such studies cannot be relied on to detect bone marrow depression prior to development of aplastic anemia. To facilitate appropriate studies and observation during therapy, it is desirable that patients be hospitalized.

Risk first

Contraindications

  • CONTRAINDICATIONS: Chloramphenicol is contraindicated in individuals with a history of previous hypersensitivity and/or toxic reaction to it.
  • It must not be used in the treatment of trivial infections or where it is not indicated, as in colds, influenza, infections of the throat
  • or as a prophylactic agent to prevent bacterial infections.

Precautions

  • Do routine blood examination, change parenteral administration to oral therapy as soon as possible, impaired liver and kidney functions.
  • Must not be used in the treatment of trivial infections.
  • Plasma concentration monitoring required in neonates and preferred in those under 4 years of age, in the elderly, and in hepatic impairment
  • recommended peak plasma concentration (approx. 1 hour after intravenous injection or infusion) 1525mg/litre
  • pre-dose (trough') concentration should not exceed 15mg/litre.

Point of care

Dosing

Adult

By mouth or by intravenous injection or infusion, 50mg/kg daily in 4 divided doses [exceptionally, can be doubled for severe infections such as septicaemia and meningitis, providing high doses reduced as soon as clinically indicated]; child, haemophilus epiglottitis and pyogenic meningitis, 50-100mg/kg daily in divided doses [high dosages decreased as soon as clinically indicated]; neonate under 2 weeks 25mg/kg daily [in 4 divided doses]; infant 2 weeks1 year 50mg/kg daily [in 4 divided doses]. Note: Plasma concentration monitoring required in neonates and preferred in those under 4 years of age, in the elderly, and in hepatic impairment; recommended peak plasma concentration [approx. 1 hour after intravenous injection or infusion] 1525mg/litre; pre-dose [ trough'] concentration should not exceed 15mg/litre.

Paediatric

Pediatric Use Precaution should be used in therapy of premature and full-term neonates and infants to avoid “gray syndrome” toxicity. Due to immature metabolic processes in the neonate and infant, excessive blood levels may result from administration of the recommended dose. The dosage should be adjusted accordingly or, preferable, the blood concentration should be determined at appropriate intervals (see ADVERSE REACTIONS , "Gray Syndrome" ). See DOSAGE AND ADMINISTRATION for dosing information in the pediatric population.

Renal

Review renal impairment dosing; many agents need CrCl/eGFR adjustment.

  • CrCl 0–120: Confirm renal dosing in product SmPC / primary label.

Hepatic

Review hepatic impairment dosing; monitor LFTs if agent is hepatically cleared or hepatotoxic.

Safety

Drug interactions

Open checker →
  • Professional use: confirm indication, dose, duration, monitoring and patient counselling points against current Kenya STG / EML and the product SmPC.
  • Document allergy status and key interactions.

Safety

Adverse effects

  • ADVERSE REACTIONS: Blood Dyscrasias The most serious adverse effect of chloramphenicol is bone marrow depression.
  • Serious and fatal blood dyscrasias (aplastic anemia, hypoplastic anemia, thrombocytopenia, and granulocytopenia) are known to occur after the administration of chloramphenicol.
  • An irreversible type of marrow depression leading to aplastic anemia with a high rate of mortality is characterized by the appearance weeks or months after therapy of bone marrow aplasia or hypoplasia.
  • Peripherally, pancytopenia is most often observed, but in a small number of cases only one or two of the three major cell types (erythrocytes, leukocytes, platelets) may be depressed.
  • A reversible type of bone marrow depression, which is dose related, may occur.
  • This type of marrow depression is characterized by vacuolization of the erythroid cells, reduction of reticulocytes and leukopenia, and responds promptly to the withdrawal of chloramphenicol.
  • An exact determination of the risk of serious and fatal blood dyscrasias is not possible because of lack of accurate information regarding 1) the size of the population at risk, 2) the total number of drug-associated dyscrasias, and 3) the total number of non-drug associated dyscrasias.
  • In a report to the California State Assembly by the California Medical Association and the State Department of Public Health in January 1967, the risk of fatal aplastic anemia was estimated at 1:24,200 to 1:40,500 based on two dosage levels.
  • There have been reports of aplastic anemia attributed to chloramphenicol which later terminated in leukemia.
  • Paroxysmal nocturnal hemoglobinuria has been reported.
  • Gastrointestinal Reactions Nausea, vomiting, glossitis and stomatitis, diarrhea and enterocolitis may occur in low incidence.
  • Neurotoxic Reactions Headache, mild depression, mental confusion, and delirium have been described in patients receiving chloramphenicol.
  • Optic and peripheral neuritis have been reported, usually following long-term therapy.
  • If this occurs, the drug should be promptly withdrawn.

Use

Indications

  • Serious infections where less potentially dangerous medicines are ineffective or contraindicated e.g. typhoid and paratyphoid fever, infections due to H. influenzae.
  • Clinical selection for Chloramphenicol should follow culture results where relevant, Kenya STG/EML recommendations, and the current product SmPC.
  • Class context: Therapeutic agent (verify pharmacological class).
  • Confirm site-specific dose, duration and monitoring before prescribing.

Pharmacology

Mode of action

Chloramphenicol is a broad-spectrum antibiotic originally isolated from Streptomyces venezuelae .

Bind ribosome Inhibit protein synthesis Bacteriostatic / cidal
Full mechanism text

Chloramphenicol is a broad-spectrum antibiotic originally isolated from Streptomyces venezuelae . It inhibits bacterial protein synthesis by interfering with the transfer of activated amino acids from soluble RNA to ribosomes. In vitro, chloramphenicol exerts mainly a bacteriostatic effect on a wide range of gram-negative and gram-positive bacteria. Antimicrobial Activity Chloramphenicol has been shown to be active against most strains of the following microorganisms, both in vitro and in clinical infections as described in the INDICATIONS AND USAGE section. Aerobic gram-negative microorganisms Haemophilus influenzae Salmonella species, including Salmonella typhi Other microorganisms Lymphogranuloma-psittacosis group Rickettsia Susceptibility Testing Methods When available, the clinical

ADME

Pharmacokinetics & PD

Onset Product-specific
Duration Product-specific
Route INTRAVENOUS
Distribution is not uniform. Highest concentrations are found in liver and kidney, and lowest concentrations are found in brain and cerebrospinal fluid. Chloramphenicol enters cerebrospinal fluid even in the absence of meningeal inflammation, appearing in concentrations about half of those fo...
Elimination of chloramphenicol in these studies ranged from a low of 68% to a high of 99% over a three-day period. From 8% to 12% of the antibiotic excreted is in the form of free chloramphenicol; the remainder consists of microbiologically inactive metabolites, principally the conjugate wit...
Full PK/PD text

CLINICAL PHARMACOLOGY: Chloramphenicol administered orally is absorbed rapidly from the intestinal tract. In controlled studies in adult volunteers using the recommended dosage of 50 mg/kg/day, a dosage of 1 g every 6 hours for 8 doses was given. Using the microbiological assay method, the average peak serum level was 11.2 mcg/mL one hour after the first dose. A cumulative effect gave a peak rise to 18.4 mcg/mL after the fifth dose of 1 g. Mean serum levels ranged from 8 to 14 mcg/mL over the 48-hour period. Total urinary excretion of chloramphenicol in these studies ranged from a low of 68% to a high of 99% over a three-day period. From 8% to 12% of the antibiotic excreted is in the form of free chloramphenicol; the remainder consists of microbiologically inactive metabolites, principally the conjugate with glucuronic acid. Since the glucuronide is excreted rapidly, most chloramphenicol detected in the blood is in the microbiologically active free form. Despite the small proportion of unchanged drug excreted in the urine, the concentration of free chloramphenicol is relatively high, amounting to several hundred mcg/mL in patients receiving divided doses of 50 mg/kg/day. Small amounts of active drug are found in bile and feces. Chloramphenicol diffuses rapidly, but its distribution is not uniform. Highest concentrations are found in liver and kidney, and lowest concentrations are found in brain and cerebrospinal fluid. Chloramphenicol enters cerebrospinal fluid even in the absence of meningeal inflammation, appearing in concentrations about half of those found in the blood. Measurable levels are also detected in pleural and in ascitic fluids, saliva, milk, and in the aqueous and vitreous humors. Transport across the placental barrier occurs with somewhat lower concentration in cord blood of neonates than in maternal blood. Microbiology Mechanism of Action Chloramphenicol is a broad-spectrum antibiotic originally isolated from Streptomyces venezuelae . It inhibits bacterial protein synthesis by interfering with the transfer of activated amino acids from soluble RNA to ribosomes. In vitro, chloramphenicol exerts mainly a bacteriostatic effect on a wide range of gram-negative and gram-positive bacteria. Antimicrobial Activity Chloramphenicol has been shown to be active against most strains of the following microorganisms, both in vitro and in clinical infections as described in the INDICATIONS AND USAGE section. Aerobic gram-negative microorganisms Haemophilus influenzae Salmonella species, including Salmonella typhi Other microorganisms Lymphogranuloma-psittacosis group Rickettsia Susceptibility Testing Methods When available, the clinical microbiology laboratory should provide cumulative reports of in vitro susceptibility test results for antimicrobial drugs used in local hospitals and practice areas to the physician as periodic reports that describe the susceptibility profile of nosocomial and community-acquired pathogens. These reports should aid the physician in selecting an antibacterial drug for treatment. Dilution Techniques Quantitative methods are used to determine antimicrobial minimum inhibitory concentrations (MICs). These MICs provide estimates of the susceptibility of bacteria to antimicrobial compounds. The MICs should be determined using a standardized (broth and/or agar). 1,3 The MIC values should be interpreted according to the criteria provided in Table 1. Diffusion Techniques Quantitative methods that require measurement of zone diameters can also provide reproducible estimates of the susceptibility of bacteria to antimicrobial compounds. The zone size should be determined using a standardized test method. 2,3 This procedure uses paper disks impregnated with 30 mcg chloramphenicol to test the susceptibility of bacteria to chloramphenicol. The disc diffusion breakpoints should be interpreted according to the criteria provided in Table 1. Table 1. Susceptibility Test Interpretive Criteria for Chloramphenicol Pathogen Minimum Inhibitory Concentrations (mcg/mL) Zone Diameters (mm) S I R S I R Salmonella spp. < 8 16 > 32 > 18 13 to 17 < 12 Haemophilus influenzae < 2 4 > 8 ≥ 29 26 to 28 < 25 A report of Susceptible (S) indicates that the antimicrobial drug is likely to inhibit growth of the pathogen if the antimicrobial drug reaches the concentration usually achievable at the site of infection. A report of Intermediate (I) indicates that the result should be considered equivocal, and, if the microorganism is not fully susceptible to alternative, clinically feasible drugs, the test should be repeated. This category implies possible clinical applicability in body sites where the drug is physiologically concentrated or in situations where a high dosage of the drug can be used. This category also provides a buffer zone that prevents small uncontrolled technical factors from causing major discrepancies in interpretation. A report of Resistant (R) indicates that the antimicrobial drug is not likely to inhibit growth of the pathogen if the antimicrobial drug reaches the concentration usually achievable at the infection site; other therapy should be selected. Quality Control Standardized susceptibility test procedures require the use of laboratory controls to monitor and ensure the accuracy and precision of supplies and reagents used in the assay, and the techniques of the individuals performing the test. 1,2,3 Standard chloramphenicol powder should provide the following range of MIC values noted in Table 2. For the disc diffusion technique using the 30 mcg disk, the criteria in Table 2 should be achieved. Table 2. Quality Control Parameters for Chloramphenicol QC Strain Minimum Inhibitory Concentrations (mcg/mL) Zone Diameters (mm) Escherichia coli ATCC 25922 2 to 8 21 to 27 Haemophilus influenzae ATCC 49247 0.25 to 1 31 to 40 Susceptibility Testing Methods When available, the clinical microbiology laboratory should provide cumulative reports of in vitro susceptibility test results for antimicrobial drugs used in local hospitals and practice areas to the physician as periodic reports that describe the susceptibility profile of nosocomial and community-acquired pathogens. These reports should aid the physician in selecting an antibacterial drug for treatment. Dilution Techniques Quantitative methods are used to determine antimicrobial minimum inhibitory concentrations (MICs). These MICs provide estimates of the susceptibility of bacteria to antimicrobial compounds. The MICs should be determined using a standardized (broth and/or agar). 1,3 The MIC values should be interpreted according to the criteria provided in Table 1. Diffusion Techniques Quantitative methods that require measurement of zone diameters can also provide reproducible estimates of the susceptibility of bacteria to antimicrobial compounds. The zone size should be determined using a standardized test method. 2,3 This procedure uses paper disks impregnated with 30 mcg chloramphenicol to test the susceptibility of bacteria to chloramphenicol. The disc diffusion breakpoints should be interpreted according to the criteria provided in Table 1. Table 1. Susceptibility Test Interpretive Criteria for Chloramphenicol Pathogen Minimum Inhibitory Concentrations (mcg/mL) Zone Diameters (mm) S I R S I R Salmonella spp. < 8 16 > 32 > 18 13 to 17 < 12 Haemophilus influenzae < 2 4 > 8 ≥ 29 26 to 28 < 25 A report of Susceptible (S) indicates that the antimicrobial drug is likely to inhibit growth of the pathogen if the antimicrobial drug reaches the concentration usually achievable at the site of infection. A report of Intermediate (I) indicates that the result should be considered equivocal, and, if the microorganism is not fully susceptible to alternative, clinically feasible drugs, the test should be repeated. This category implies possible clinical applicability in body sites where the drug is physiologically concentrated or in situations where a high dosage of the drug can be used. This category also provides a buffer zone that prevents small uncontrolled technical factors from causing major discrepancies in interpretation. A report of Resistant (R) indicates that the antimicrobial drug is not likely to inhibit growth of the pathogen if the antimicrobial drug reaches the concentration usually achievable at the infection site; other therapy should be selected. Quality Control Standardized susceptibility test procedures require the use of laboratory controls to monitor and ensure the accuracy and precision of supplies and reagents used in the assay, and the techniques of the individuals performing the test. 1,2,3 Standard chloramphenicol powder should provide the following range of MIC values noted in Table 2. For the disc diffusion technique using the 30 mcg disk, the criteria in Table 2 should be achieved. Table 2. Quality Control Parameters for Chloramphenicol QC Strain Minimum Inhibitory Concentrations (mcg/mL) Zone Diameters (mm) Escherichia coli ATCC 25922 2 to 8 21 to 27 Haemophilus influenzae ATCC 49247 0.25 to 1 31 to 40

Kenya

Brands & prices

7 listed
Brand Company Pack KES
Biophenicol Biodeal Laboratories Ltd. Standard Commercial Pack
Chloramphenicol Macleods Macleods Pharmaceuticals Ltd. Standard Commercial Pack
Chlorocide Regal Pharmaceuticals Standard Commercial Pack
Dawaphenicol suspension Dawa Limited Standard Commercial Pack
Kloran Sphinx Pharmaceuticals Ltd Standard Commercial Pack
Mediphenicol Independent / Registered Supplier Standard Commercial Pack
Oramnicol Laboratory & Allied Ltd. Standard Commercial Pack

Special populations

Pregnancy & lactation

Pregnancy

Pregnancy Pregnancy Category C – Animal reproduction studies have not been conducted with chloramphenicol. There are no adequate and well-controlled studies to establish safety of this drug in pregnancy. It is not known whether chloramphenicol can cause fetal harm when administered to a pregnant woman. Orally administered chloramphenicol has been shown to cross the placental barrier. Because of potential toxic effects on the fetus (see ADVERSE REACTIONS, “Gray Syndrome” ), chloramphenicol should be given to a pregnant woman only if the potential benefit justifies the potential risk to the fetus.

Lactation

Nursing Mothers Chloramphenicol is excreted in human milk following oral administration of the drug. Because of the potential for serious adverse reactions in nursing infants from chloramphenicol, a decision should be made whether to discontinue nursing or to discontinue the drug, taking into account the importance of the drug to the mother (see ADVERSE REACTIONS, “Gray Syndrome” ).

Diet

Food & alcohol

  • Drug & food interactions (label) Drug Interactions Concurrent therapy with other drugs that may cause bone marrow depression should be avoided.

Trust

Sources & disclaimer

Source: Local active-ingredient clinical extract; FDA drug label via OpenFDA/DailyMed; Professional class pharmacology (Therapeutic agent (verify pharmacological class))

Open source link

Last reviewed: 01 Aug 2026

Decision support only — not a substitute for clinical judgment, product SmPC, or Kenya STG/EML.

Kenya Verified Health Registry